The MDS entities were as follows: MDS with defining genetic aberrations [MDS with low blasts (<5%) and isolated deletion of chromosome 5q or del(5q) (MDS-5q); MDS with low blasts and SF3B1 gene mutation (MDS-SF3B1); MDS with biallelic TP53 mutation (MDS-biTP53)] and MDS morphologically defined [MDS with low blasts, <5% marrow blasts (MDS-LB); MDS, hypoplastic; MDS with increased blasts (MDS-IB) that include MDS-IB1 with 5–9% marrow blasts; MDS-IB2 with 10–19% marrow blasts; MDS with fibrosis [1]. The gene discussed is TP53; the disease is myelodysplastic syndrome.